相关实验视频

Updated: Mar 11, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

国内工程水稳定静脉注射纳米颗粒使得Ticagrelor的体内逆转成为可能

Wenchuang Yang^1,2,3, Yabing Tan^1,4, Jiajia Zheng⁵

¹CAS Key Laboratory For Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, China.

Angewandte Chemie (International ed. in English)

|March 10, 2026

概括

研究人员开发了一个金纳米粒子平台,以中和抗血小板药物Ticagrelor. 这种新型纳米系统有效地逆转了Ticagrelor.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
药用化学医学化学

背景情况:

二醇在生物系统和药物结构中至关重要.
在活体中准生物活性cis-diols是具有挑战性的.
提卡格勒勒是一种含有cis-diol的抗血小板药物.

研究的目的:

开发一个平台,用于体内识别和功能性操纵cis-diols.
创建一种方法来逆转Ticagrelor的抗血小板活性.
设计一种用于向药物中和的纳米材料.

主要方法:

黄金纳米颗粒 (AuNPs) 的功能化用酸和o-carborane.
利用o-carborane破坏P2Y12-Ticagrelor结合的能力.
采用碳化合物衍生型的 counterions,以提高溶解度和稳定性.
开发一种用于药物中和的静脉纳米系统.

主要成果:

酸功能化的AuNP平台可以选择性地准和中和Ticagrelor.
该o-carborane装饰增强了结合破坏和纳米粒子稳定性.
电流工程提高了水溶性,同时保持了酸的完整性.
在小鼠和猪出血模型中,证明了逆转蒂卡格勒的高疗效.

结论:

这项研究提出了第一个 in vivo Ticagrelor逆转的化学策略.
开发的纳米系统为管理抗血小板药物活性提供了一种新的方法.
该平台为生物环境中的cis-diol向和纳米材料设计提供了一个广泛适用的框架.

关键词:

抗血栓治疗是一种抗血栓治疗.碳二甲酸盐是一种碳酸盐.集群集群是一个集群集群.应对策略与其他战略.反转试剂的反转试剂是什么

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...